Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Lymphoma 15Neutropenia 9Lymphoma, Large B-Cell, Diffuse 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Triple Negative Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Hodgkin Disease 4Chemotherapy-induced Neutropenia 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Colorectal Neoplasms 3Burkitt Lymphoma 3Breast Neoplasms, Male 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma of Lung 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × pegfilgrastim × Clear all
NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡